Viking Therapeutics shares fall 7.57% premarket after Q2 net loss widens, misses expectations.

Thursday, Jul 24, 2025 5:34 am ET1min read
Viking Therapeutics, Inc. fell 7.57% in premarket trading, with the company reporting a wider net loss for Q2 2025, missing expectations. The company's shares fell after hours following the earnings report, which highlighted a widening loss and missed expectations.

Viking Therapeutics shares fall 7.57% premarket after Q2 net loss widens, misses expectations.

Comments



Add a public comment...
No comments

No comments yet